Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype

Table 2 Baseline characteristics (modified intent to treat population)

	Non-expresser (n = 15)	Intermediate metabolizer (n = 13)	Extensive metabolizer (n = 6)	P value
Age (yr), mean ± SD	53.8 ± 12.6	49.0 ± 14.0	58.3 ± 14.1	0.354
Male, n (%)	9 (60.0)	8 (61.5)	2 (33.3)	0.470
Race, n (%)				0.026
White	7 (46.7)	1 (7.7)	0
Black	7 (46.7)	12 (92.3)	5 (83.3)
Hispanic	1 (6.7)	0	0
Transplant type, n (%)				0.550
Deceased donor	12 (80.0)	8 (61.5)	4 (66.7)
Living donor	3 (20.0)	5 (38.5)	2 (33.3)
Hypertension, n (%)	12 (80.0)	9 (69.2)	6 (100.0)	0.304
Diabetes mellitus, n (%)	2 (13.3)	4 (30.8)	2 (33.3)	0.457
Focal segmental glomerulosclerosis, n (%)	1 (6.7)	0	0	0.521
Polycystic kidney disease, n (%)	0	1 (7.7)	0	0.435
HIV-associated nephropathy, n (%)	1 (6.7)	0	0	0.521
Lupus nephritis, n (%)	0	1 (7.7)	0	0.435
Transplant number, n (%)				0.435
One	15 (100.0)	12 (92.3)	6 (100.0)
Two	0	1 (7.7)	0
cPRA (%), median (IQR)	0 (0-20.8)	10.0 (0-10.0)	0 (0-20.8)	0.732
Actual body weight (kg), mean ± SD	85.5 ± 16.8	91.8 ± 22.2	77.4 ± 10.5	0.286
Dosing weight, n (%)				0.987
Actual	7 (53.3)	6 (53.8)	3 (50.0)
Adjusted	8 (46.7)	7 (46.2)	3 (50.0)
BMI (kg/m2), mean ± SD	29.68 ± 5.0	30.68 ± 6.9	28.88 ± 4.5	0.805

BMI: Body mass index; cPRA: Calculated panel reactive antibody; IQR: Interquartile range; HIV: Human immunodeficiency virus.